29 January 2019 - Fast track designation is based on the evaluation of Phase I results demonstrating strong clinical activity, favourable safety and substantial improvement in quality of life.

Innate Pharma announced today that the US FDA has granted fast track designation to IPH4102 for the treatment of adult patients with relapsed or refractory Sézary syndrome who have received at least two prior systemic therapies. 

IPH4102 is Innate Pharma’s wholly-owned first-in-class anti-KIR3DL2 antibody, developed for the treatment of T-cell lymphoma.

Read Innate Pharma press release